Analysis of the dose-dependent risk factors of the GLP-1 receptor agonist and the societal normalization of the drug for cosmetic use
Location
Suwanee, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
Introduction:
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that bind to GLP-1 receptors in the pancreas, hypothalamus, liver, and gastrointestinal tract, stimulating insulin release, delaying gastric emptying, and promoting satiety. Originally FDA approved in 2005 for patients with type 2 diabetes, their mechanism targeting multiple organs led to weight loss in patients. In 2021, the FDA approved semaglutide 2.4 mg, the active ingredient in Wegovy and Ozempic, for the treatment of obesity. Its popularity for cosmetic weight loss among social media and celebrity use makes it an ideal candidate to explore dose-dependent risks associated with unintended use to raise awareness of the importance of proper monitoring when taking this medication.
Objective:
To educate physicians and the general public about the mechanistic rationale, efficacy, and safety of the GLP-1 agonists when used for type 2 diabetes versus obesity, and to highlight these safety profiles in the context of using these drugs for cosmetic weight loss.
Methods:
A systematic review was conducted using PubMed, Google Scholar, Web of Science, ScienceDirect, and ACP resources. Phase II–III randomized controlled trials evaluating GLP-1 receptor agonists in T2DM and obesity were included. Major diabetes trials reviewed included LEADER (liraglutide 1.8 mg daily), SUSTAIN-6 (semaglutide 0.5–1.0 mg weekly), and REWIND (dulaglutide 1.5 mg weekly), which primarily assessed glycemic control and cardiovascular outcomes. Obesity-focused trials included SCALE (liraglutide 3.0 mg daily), the STEP series (semaglutide 2.4 mg weekly), and SURMOUNT-1/2 (tirzepatide up to 15 mg weekly). Extracted data included percent weight loss, gastrointestinal adverse events, and rare adverse effects (pancreatitis, gallbladder disease) for each intended use of the drug.
Results:
Major randomized controlled trials demonstrate that GLP-1 receptor agonists produce favorable outcomes for their intended use but still show dose-dependent risks. In type 2 diabetes, LEADER, SUSTAIN-6, and REWIND clinical trials showed favorable outcomes in reducing blood glucose levels, which also led to improved cardiovascular health. When used for weight loss in obese patients, SCALE, STEP, and SURMOUNT 1/2 achieved greater weight loss. The higher drug doses in these trials also led to various adverse effects—including nausea, vomiting, and diarrhea—occurring in up to 50% of patients. Additional reported risks include biliary disease, rare severe hypoglycemia when combined with insulin or sulfonylureas, and emergency visits related to dehydration, acute kidney injury, gallstones, and pancreatitis, especially with the high drug dose regimens.
Conclusion:
GLP-1 has been widely normalized through mainstream media, social media popularity, and increased celebrity usage, which has shifted the focus of the medication from its therapeutic usage intended for patients who suffer from obesity and type 2 diabetes to an aesthetic focus. Individuals who seek GLP-1 receptor agonists for cosmetic weight loss can be exposed to avoidable harm, which is why physicians must clearly differentiate the proper dosing for the drug and spread public awareness on the adverse dose-dependent outcomes of this drug.
Embargo Period
5-13-2026
Analysis of the dose-dependent risk factors of the GLP-1 receptor agonist and the societal normalization of the drug for cosmetic use
Suwanee, GA
Introduction:
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that bind to GLP-1 receptors in the pancreas, hypothalamus, liver, and gastrointestinal tract, stimulating insulin release, delaying gastric emptying, and promoting satiety. Originally FDA approved in 2005 for patients with type 2 diabetes, their mechanism targeting multiple organs led to weight loss in patients. In 2021, the FDA approved semaglutide 2.4 mg, the active ingredient in Wegovy and Ozempic, for the treatment of obesity. Its popularity for cosmetic weight loss among social media and celebrity use makes it an ideal candidate to explore dose-dependent risks associated with unintended use to raise awareness of the importance of proper monitoring when taking this medication.
Objective:
To educate physicians and the general public about the mechanistic rationale, efficacy, and safety of the GLP-1 agonists when used for type 2 diabetes versus obesity, and to highlight these safety profiles in the context of using these drugs for cosmetic weight loss.
Methods:
A systematic review was conducted using PubMed, Google Scholar, Web of Science, ScienceDirect, and ACP resources. Phase II–III randomized controlled trials evaluating GLP-1 receptor agonists in T2DM and obesity were included. Major diabetes trials reviewed included LEADER (liraglutide 1.8 mg daily), SUSTAIN-6 (semaglutide 0.5–1.0 mg weekly), and REWIND (dulaglutide 1.5 mg weekly), which primarily assessed glycemic control and cardiovascular outcomes. Obesity-focused trials included SCALE (liraglutide 3.0 mg daily), the STEP series (semaglutide 2.4 mg weekly), and SURMOUNT-1/2 (tirzepatide up to 15 mg weekly). Extracted data included percent weight loss, gastrointestinal adverse events, and rare adverse effects (pancreatitis, gallbladder disease) for each intended use of the drug.
Results:
Major randomized controlled trials demonstrate that GLP-1 receptor agonists produce favorable outcomes for their intended use but still show dose-dependent risks. In type 2 diabetes, LEADER, SUSTAIN-6, and REWIND clinical trials showed favorable outcomes in reducing blood glucose levels, which also led to improved cardiovascular health. When used for weight loss in obese patients, SCALE, STEP, and SURMOUNT 1/2 achieved greater weight loss. The higher drug doses in these trials also led to various adverse effects—including nausea, vomiting, and diarrhea—occurring in up to 50% of patients. Additional reported risks include biliary disease, rare severe hypoglycemia when combined with insulin or sulfonylureas, and emergency visits related to dehydration, acute kidney injury, gallstones, and pancreatitis, especially with the high drug dose regimens.
Conclusion:
GLP-1 has been widely normalized through mainstream media, social media popularity, and increased celebrity usage, which has shifted the focus of the medication from its therapeutic usage intended for patients who suffer from obesity and type 2 diabetes to an aesthetic focus. Individuals who seek GLP-1 receptor agonists for cosmetic weight loss can be exposed to avoidable harm, which is why physicians must clearly differentiate the proper dosing for the drug and spread public awareness on the adverse dose-dependent outcomes of this drug.